All In Biotech

Drug Trial Radar · NCT05974267

Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2)

Phase 2a Proof-of-Concept, Multicenter, Randomized, Open Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of a Single Dose of the Combination M5717-pyronaridine as Chemoprevention in Asymptomatic Adults and Adolescents With Plasmodium Falciparum Malaria Infection (CAPTURE-2)

Last checked: Nov 19, 2026Latest source record: Feb 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 192 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

192

Actual

Start

Nov 28, 2023

Primary completion

Dec 29, 2024

Study completion Dec 29, 2024

Sponsor

Sponsor type
Industry
First posted
Aug 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the efficacy and safety of a single dose of M5717 plus pyronaridine tetraphosphate in clearing current Plasmodium falciparum infection and protecting against recurrent infections in asymptomatic adults and adolescents. The study will also assess the duration of protection provided by different doses of M5717 plus pyronaridine and the additional contribution of M5717 to the duration of protection using external study data.

Conditions

  • Malaria Infection

Interventions

  • M5717 60 mgDrug

    Participants received single oral dose (Capsules) of 60 mg M5717 on Day 1 under fasting condition

  • PyronaridineDrug

    Participants received Pyronaridine tablets orally single dose of 720 (Participants \>= 65 kg) and 540 mg (Participants \>= 45 to \< 65 kg) on Study Day 1 under fasting condition

  • Atovaquone-ProguanilDrug

    Participants received Atovaquone-Proguanil tablets 1000/400 mg once daily in a 3-day treatment regimen.

  • M5717 200 mgDrug

    Participants received single oral dose (Capsules) of 200 mg M5717 on Day 1 under fasting condition

  • M5717 660mgDrug

    Participants received single oral dose (Capsules) of 660 mg M5717 on Day 1 under fasting condition

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Parasitemia Since Negative Blood Smear After TreatmentTime frame: From treatment Day 1 up to End of observation period Day 64 (Week 10)

Locations

4 sites in 4 countries. Site status is shown where the registry gives one.

  • Groupe de Recherche Action en Sante (GRAS)

    Ouagadougou, Burkina Faso

  • Kisumu County Referral Hospital

    Kisumu, Kenya

  • MRC Unit The Gambia at LSHTM

    Banjul, The Gambia

  • Ndola Teaching Hospital

    Ndola, Zambia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.